© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 24, 1834-1839,
December 18, 1996
© 1996 Oxford University Press
Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer
Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials GroupCorrespondence to: Cancer Research Campaign (CRC) Over Fifties Trial Coordinator, CRC Clinical Trials Centre, Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, U.K.
BACKGROUND: Although trials of postsurgical tamoxifen therapy for patients with breast cancer have convincingly demonstrated reductions in relapse rates and improvements in survival, the optimal duration of therapy is as yet unclear. Purpose: Our objective is to determine whether 2 or 5 years of tamoxifen therapy (20mg/day orally) is preferable in the treatment of patients with early breast cancer.
METHODS: A randomized trial that was pragmatic in policy, allowing flexibility in primary treatment (i.e., type of surgery) and adjuvant therapy other than tamoxifen (i.e., radiotherapy or chemotherapy), was used to encourage maximum participation of clinicians and patients. This design allowed comparison of the two durations of tamoxifen therapy under conditions in which they would subsequently be applied in clinical practice. The patients were recruited from the oncology departments of participating hospitals in the U.K., Belgium, Poland, and Hong Kong. Those women who had completed an initial 2year course of tamoxifen therapy after primary surgery and had not experienced a recurrence of breast cancer were asked to consider random assignment either to no further therapy or to an additional 3 years of tamoxifen. Follow-up reports (every 6 months for 3 years after random assignment and then annually) were required for all surviving study subjects. These reports recorded all breast cancer-related events (i.e., locoregional relapse and distant metastasis) or the development of new primary tumors (in the opposite breast or at any other site). For patients who died, the date and cause of death were recorded. Event-free survival; overall survival; and time to locoregional relapse, distant metastasis, or the development of new primary cancers were end points for the analysis. Survival comparisons were made by use of life tables and the logrank test. Reported P values are two-sided.
RESULTS: By December 31, 1994, 2937 patients had accepted random assignment to treatment; 1470 were assigned to stop tamoxifen therapy after having received it for 2 years and 1467 were assigned to continue therapy for an additional 3 years (total, 5 years). An analysis was performed when the target for patient accrual had been reached, although the trial remains open. At a median follow-up of 2 years since the randomization, no difference in survival between the two treatment groups was detected (relative risk = 0.89; 95% confidence interval = 0.69–1.15), but a statistically significant delay in the time to relapse for patients receiving the longer treatment was demonstrated (relative risk = 0.81; 95% confidence interval = 0.69–0.98).
CONCLUSIONS AND IMPLICATIONS: Our results suggest that 5 years may be better than 2 years of tamoxifen therapy, but more evidence regarding the optimal duration of tamoxifen therapy must be obtained. [J Natl Cancer Inst 1996; 88: 1834–9]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. P. Mamounas Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings Ann. Surg. Oncol., March 1, 2008; 15(3): 691 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L Jones and A. U Buzdar A review of adjuvant hormonal therapy in breast cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 391 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Coombes, E. Hall, L. J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S. E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer N. Engl. J. Med., March 11, 2004; 350(11): 1081 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sacco, M. Valentini, M. Belfiglio, F. Pellegrini, G. De Berardis, M. Franciosi, and A. Nicolucci Randomized Trial of 2 Versus 5 Years of Adjuvant Tamoxifen for Women Aged 50 Years or Older With Early Breast Cancer: Italian Interdisciplinary Group for Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01 J. Clin. Oncol., June 15, 2003; 21(12): 2276 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schmid, R. Jakesz, H. Samonigg, E. Kubista, M. Gnant, C. Menzel, M. Seifert, K. Haider, S. Taucher, B. Mlineritsch, et al. Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6 J. Clin. Oncol., March 15, 2003; 21(6): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bryant, B. Fisher, and J. Dignam Duration of Adjuvant Tamoxifen Therapy J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fisher, J. Dignam, J. Bryant, and N. Wolmark Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial J Natl Cancer Inst, May 2, 2001; 93(9): 684 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Delozier, M. Spielmann, J. Mace-Lesec'h, M. Janvier, C. Hill, B. Asselain, J.-P. Julien, B. Weber, L. Mauriac, J.-C. Petit, et al. Tamoxifen Adjuvant Treatment Duration in Early Breast Cancer: Initial Results of a Randomized Study Comparing Short-Term Treatment With Long-Term Treatment J. Clin. Oncol., October 20, 2000; 18(20): 3507 - 3512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ménard, P. Aiello, E. Tagliabue, C. Rumio, P. L. Lollini, M. I. Colnaghi, and A. Balsari Tamoxifen Chemoprevention of a Hormone-independent Tumor in the Proto-neu Transgenic Mice Model Cancer Res., January 1, 2000; 60(2): 273 - 275. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Baum and J. Houghton Contribution of randomised controlled trials to understanding and management of early breast cancer BMJ, August 28, 1999; 319(7209): 568 - 571. [Full Text]
|
|
|
|
|
|
C. K. Osborne Tamoxifen in the Treatment of Breast Cancer N. Engl. J. Med., November 26, 1998; 339(22): 1609 - 1618. [Full Text] [PDF]
|
|
|
|
|
|
D. Rea, C. Poole, and R. Gray Adjuvant tamoxifen: how long before we know how long? BMJ, May 16, 1998; 316(7143): 1518 - 1519. [Full Text]
|
|
|
|
 |
|
 C. A. Hudis and L. Norton Adjuvant Drug Treatment for Resectable Breast Cancer Oncologist, December 1, 1997; 2(6): 351 - 358. [Abstract] [Full Text] [PDF]
|
|